Ophthalmic drugs monograph
This article was originally published in The Tan Sheet
Executive Summary
FDA is updating its OTC ophthalmic drug products final monograph "to be consistent with" USP name change for active ingredient hydroxypropyl methylcellulose that took effect in September 2002, agency says in 1June 3 Federal Register notice. New name for active ingredient is hypromellose, FDA notes. Manufacturers of OTC ophthalmic drug products will have until Sept. 1 to implement labeling changes, agency adds...
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.